Atlas Brown’s Novo Nordisk NVO Stock Holding History

Atlas Brown’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,499	Closed	-$250K	–	231
2025 Q3	$250K	Sell	4,499 -4,526	-50%	-$265K	0.07%	198
2025 Q2	$623K	Buy	9,025 +933	+12%	+$63.5K	0.2%	107
2025 Q1	$562K	Buy	8,092 +2,962	+58%	+$245K	0.2%	111
2024 Q4	$441K	Buy	5,130 +1,285	+33%	+$139K	0.15%	133
2024 Q3	$458K	Sell	3,845 -438	-10%	-$58.4K	0.16%	132
2024 Q2	$611K	Buy	4,283 +460	+12%	+$61K	0.22%	108
2024 Q1	$491K	Buy	3,823 +95	+3%	+$11.3K	0.18%	117
2023 Q4	$386K	Hold	3,728	–	–	0.16%	128
2023 Q3	$339K	Hold	3,728	–	–	0.15%	132
2023 Q2	$302K	Hold	3,728	–	–	0.13%	142
2023 Q1	$297K	Buy	3,728 +8	+0.2%	+$567	0.14%	139
2022 Q4	$252K	Buy	+3,720	New	+$218K	0.12%	153
2022 Q3	–	Sell	-3,720	Closed	-$207K	–	174
2022 Q2	$207K	Hold	3,720	–	–	0.1%	165
2022 Q1	$207K	Hold	3,720	–	–	0.08%	180
2021 Q4	$208K	Buy	+3,720	New	+$202K	0.08%	184

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Atlas Brown's NVO Position: Q4 2025 in Review

Atlas Brown sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 4,499 shares — an estimated $250K sold.

Atlas Brown first reported a position in NVO in Q4 2021 and held it in 15 quarters. The position peaked at $623K in Q2 2025. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Atlas Brown reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Atlas Brown sold 4,499 Novo Nordisk shares in Q4 2025, an estimated $250K.
Atlas Brown first reported a position in Novo Nordisk in Q4 2021 and held it in 15 quarters.
Atlas Brown's Novo Nordisk position peaked at $623K in Q2 2025.
1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Atlas Brown's 13F filing for Q4 2025, filed 9 Jan 2026.